Obicetrapib (AMG-899,TA-8995)|CETP inhibitor|CAS 866399-87-3

Cas No.:	866399-87-3
Chemical Name:	4-((2-((3,5-bis(trifluoromethyl)benzyl)((2R,4S)-1-(ethoxycarbonyl)-2-ethyl-6-
Synonyms:	AMG 899,TA 8995,AMG899,TA8995,
SMILES:	O=C(O)CCCOC1=CN=C(N(CC2=CC(C(F)(F)F)=CC(C(F)(F)F)=C2)[C@H]3C[C@@H](CC)N(C(OCC)=O)C4=C3C=C(C(F)(F)F)C=C4)N=C1
Formula:	C₃₂H₃₁F₉N₄O₅
M.Wt:	722.6
Purity:	>98%
Sotrage:	2 years -20°C Powder, 2 weeks 4°C in DMSO, 6 months -80°C in DMSO
Publication:	1. Ford J, et al. Br J Clin Pharmacol. 2014 Sep;78(3):498-508. 2. Hovingh GK, et al. Lancet. 2015 Aug 1;386(9992):452-60.

Description:

Obicetrapib (also known as AMG-899, TA-8995, and DEX-001) is a cholesteryl ester transfer protein (CETP) inhibitor. CETP inhibitors substantially increase the concentration of high-density lipoprotein cholesterol (HDL-C), which may have a possible beneficial effect for cardiovascular disease risk reduction.

MSDS

COA

LOT NO.	DOWNLOAD

2018-0101
2018-0101

Cat. No.	Product name	Field of application
DC10134	Obicetrapib (AMG-899,TA-8995)	Obicetrapib is a CETP inhibitor, on the elevation of high-density lipoprotein cholesterol (HDL-C) and reduction of low-density lipoprotein cholesterol (LDL-C), alone and in combination with statin therapy.